PharmAust (ASX: PAA) confirms monepantel's anti-viral potential in fight against COVID-19 (w/ Roger Aston)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the company's latest news on monepantel which is set to commence a Phase 1 COVID-19 trial in humans in the near term. This comes after successfully repeating a second round of in-vitro anti-viral confirmatory testing, demonstrating anti-SARS-CoV-2 activity of both its monepantel and monepantel sulfone drug candidates. Dr Aston also discusses US veterinary pharmaceutical company Elanco US Inc decision not to proceed with exercising its option to develop monepantel as a cancer treatment for dogs and what this means for the company.